Table 3.
Recommended doses of the dabigatran etexilate, rivaroxaban, and apixaban for approved indications in the United States (2013)
QD indicates daily.
*Pradaxa (dabigatran etexilate mesylate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc.
†Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc.
‡Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co.
